Overview

Edwards Lifesciences (NYSE:EW) shares increased by 3.6% on Tuesday following the publication of a U.S. government National Coverage Decision (NCD) proposal that loosens restrictions on transcatheter aortic‑valve replacement (TAVR) procedures.

Key Provisions of the NCD Proposal

  • The memo extends coverage to patients with asymptomatic severe aortic stenosis, placing the indication under a coverage‑with‑evidence‑development framework.
  • It eliminates the requirement for a dual‑operator intra‑operative setup, allowing a single physician to perform the procedure.
  • Various hospital‑level volume requirements are removed, reducing the minimum case numbers previously needed for a center to be eligible for reimbursement.
  • Additional unspecified restrictions are also relaxed, creating a more permissive environment for TAVR adoption.

Analyst Reactions

  • Vijay Kumar (Evercore ISI), who rates EW as outperform, described the memo as an “uber bullish scenario,” noting that every key metric anticipated by bullish investors was proposed and that lower volume thresholds could enable more hospitals to launch TAVR programs.
  • Mike Kratky (Leerink Partners), maintaining a market‑perform rating, said the updates are “incrementally positive,” expecting enhanced procedural efficiency at existing TAVR centers and reduced barriers for new programs.
  • Richard Newitter (Truist), with a hold rating, highlighted that the decision memo boosts confidence in an “8%+ TAVR trajectory” for Edwards into 2027 and suggests further upside toward the firm’s $90 price target, also noting ongoing share gains for Medtronic and Boston Scientific.

Market Reaction

  • Medtronic (NYSE:MDT) shares rose 0.91% and Abbott Laboratories (NYSE:ABT) shares rose 0.30% on the same news, reflecting broader market optimism for the TAVR space.
  • Boston Scientific was mentioned as experiencing continued share gains, though specific percentage movement was not disclosed.

Additional Information

The article was generated with AI assistance and reviewed by an editor, as noted in the footer.